MRCL3 Antibody [mFluor Violet 500 SE]

Product Discontinued

MRCL3 Antibody [mFluor Violet 500 SE] Summary

• Immunogen: myosin, light chain 12A, regulatory, non-sarcomeric. (Uniprot# P19105)
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MYL12A
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunohistochemistry
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Immunogen affinity purified

Notes

mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Alternate Names for MRCL3 Antibody [mFluor Violet 500 SE]

• MLCBMyosin RLC
• MRCL3
• MRLC3MLC-2B
• MYL2B
• myosin regulatory light chain 12A
• Myosin regulatory light chain 2, nonsarcomeric
• myosin regulatory light chain 3
• myosin regulatory light chain MRCL3
• Myosin regulatory light chain MRLC3
• myosin, light chain 12A, regulatory, non-sarcomeric
• myosin, light polypeptide, regulatory, non-sarcomeric (20kD)
• RLC

Background

The muscle myosins and hexomeric proteins consisting of two heavy chains and two pairs of light chains, the latter called essential (ELC) and regulatory (RLC). The light chains stabilize the long alpha helical neck of the myosin head (1). Human myosin light chain-2 (MYL2) is an important protein involved in the regulation of myosin ATPase activity in smooth muscle. In cardiac muscle, the precise role of MYL2 is not well understood; however, an increase in ventricular MYL2 is observed during myocardial hypertrophy in cardiac patients with valve stenosis (2). Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease caused by mutations in all of the major sarcomeric proteins, including the ventricular myosin regulatory light-chain (RLC). The Myosin RLC mutation has been associated with a rare variant of cardiac hypertrophy defined by mid-left ventricular obstruction due to papillary muscle hypertrophy. This mutation was later found to cause ventricular and septal hypertrophy (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MYL12A